Clinical Trials Logo

Ovarian Cancer clinical trials

View clinical trials related to Ovarian Cancer.

Filter by:

NCT ID: NCT05086692 Recruiting - Colorectal Cancer Clinical Trials

A Beta-only IL-2 ImmunoTherapY (ABILITY) Study

Start date: August 27, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

NCT ID: NCT05082025 Not yet recruiting - Ovarian Cancer Clinical Trials

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

Start date: February 28, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of copanlisib in combination with fulvestrant in advanced hormone receptor-positive (HR+) solid tumors harboring alterations that activate the Phosphatidylinositol-3 kinase (PI3K) pathway.

NCT ID: NCT05080946 Recruiting - Ovarian Cancer Clinical Trials

Using Aspirin to Improve Immunological Features of Ovarian Tumors

Start date: October 1, 2021
Phase: Early Phase 1
Study type: Interventional

The purpose of the study is to evaluate the effectiveness of aspirin with neoadjuvant chemotherapy for decreasing markers or immune suppression in the tumor at interval debulking surgery, in women with diagnosed ovarian, fallopian tube, or peritoneal carcinoma

NCT ID: NCT05080556 Not yet recruiting - Ovarian Cancer Clinical Trials

Adaptive Therapy (AT) With Carboplatin in Patients With Relapsed Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer

ACTOv
Start date: June 1, 2022
Phase: Phase 2
Study type: Interventional

ACTOv will compare standard 3-weekly carboplatin (AUC5), to carboplatin delivered according to an AT regimen. The AT regimen will modify carboplatin dose according to changes in the clinical-standard serum biomarker CA125 as a proxy measure of total tumour burden and an individual patient's response to the most recent chemotherapy treatment. AT could prolong sensitivity to carboplatin and extend tumour control, while simultaneously reducing chemotherapy dose and drug-induced toxicity. Carboplatin is a low cost and low toxicity drug that has an enduring and central role in ovarian cancer treatment.

NCT ID: NCT05071937 Not yet recruiting - Ovarian Cancer Clinical Trials

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

Start date: October 2021
Phase: Phase 2
Study type: Interventional

This Phase 2, open label, study with safety lead in of oral talazoparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with recurrent ovarian, fallopian tube or primary peritoneal carcinoma.

NCT ID: NCT05069818 Not yet recruiting - Ovarian Cancer Clinical Trials

Variance of HRD From Paired Ovarian Cancer

HOPEII
Start date: October 2021
Phase:
Study type: Observational

Homologous recombination deficiency (HRD) is an important biomarker of poly (ADP-ribose) polymerase inhibitor (PARPi) in patients with high-grade serous ovarian cancer (HGSOC). The stability of HRD in the recurrent HGSOC and its primary pair remains unknown.

NCT ID: NCT05065021 Not yet recruiting - Ovarian Cancer Clinical Trials

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Start date: December 6, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to see how useful it is to look at biomarkers in the blood and tumor tissue of participants with ovarian, fallopian tube or primary peritoneal cancer who have previously received treatment with a drug called a PARP inhibitor, and using the results to determine the best treatment for these participants. Biomarkers are molecules such as genes (molecules that contain instructions for the development and function of cells in the body) and proteins that may be used to see how well a body responds to certain treatments.

NCT ID: NCT05061537 Not yet recruiting - Colorectal Cancer Clinical Trials

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Start date: October 21, 2021
Phase: Phase 1
Study type: Interventional

This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and expansion study intended to evaluate the safety, viral load kinetics and shedding, pharmacodynamic, and anti-tumor activity of PF-07263689, either alone or in combination with sasanlimab (an investigational anti-programmed cell death protein 1 [PD-1] antibody), in patients with selected locally advanced or metastatic solid tumors who have exhausted all available standard of care therapies available to them. The study consists of 2 parts: Part 1 dose escalation for PF-07263689 monotherapy (Part 1A) and in combination with sasanlimab (Part 1B), followed by Part 2 dose expansion for the combination therapy.

NCT ID: NCT05059782 Recruiting - Ovarian Cancer Clinical Trials

Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer

Start date: October 10, 2021
Phase: N/A
Study type: Interventional

In this study, The researchers sought to explore the efficacy and safety of involving field radiotherapy in the oligo-metastatic/recurrent/refractory ovarian cancer patients among different groups which include drug therapy alone, radiotherapy alone, and drug therapy plus radiotherapy by inviting clinical multi-center participation.

NCT ID: NCT05059522 Recruiting - Ovarian Cancer Clinical Trials

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Start date: September 29, 2021
Phase: Phase 3
Study type: Interventional

This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.